

23 March 2017

### **Cancer Survivor Campaign Update**

Resonance Health (ASX:RHT) is pleased to provide an update on the cancer survivor campaign launched in September 2016. The campaign targets clinicians managing survivors of cancer and aims to educate and share knowledge on the risk of iron toxicity and fatty liver as a result of cancer treatment regimes. FerriScan®, the globally recognised gold standard for the measurement of liver iron concentration (LIC), and HepaFat-Scan®, for the measurement of volumetric liver fat fraction (VLFF), have the potential to significantly improve patient outcomes in this setting. The goal of the campaign is the widespread uptake of FerriScan and HepaFat-Scan for the routine clinical monitoring and management in the large and growing population of cancer survivors.

#### **Clinical Survey**

The Company has recently conducted a global clinical survey that engaged over 30 clinical experts to collect further data on current practice in iron monitoring of transfused cancer survivors and to promote any immediate opportunity to improve screening using FerriScan. Approximately 30% of cancer survivors are likely to have received blood transfusions as part of their treatment and therefore may be at risk of developing iron overload. A remarkable 93% of participants thought that iron monitoring practices could be improved at their centres. Expressions of interest were also received by 62% of respondents to participate in an audit of their patients; which would see these healthcare providers use FerriScan under their standard Service Agreement to determine the extent of iron overload in their cancer survivor cohorts.

#### **Conference Attendance**

Attendance at cancer survivor conferences is key to the promotion of FerriScan and HepaFat-Scan in this population and pivotal in exploring options for their inclusion in patient management guidelines.

The Cancer Survivorship Summit in the UK was attended by the Resonance Health UK team who networked with a diverse group of clinicians, service commissioners, and patients on the topic of iron toxicity and fatty liver in cancer survivors. Follow up meetings have been arranged with key stakeholders to continue education and explore the potential to add FerriScan and HepaFat-Scan to National Health Service (NHS) of England initiatives and guidelines on the management of cancer survivors.

Pro-active networking was also undertaken at the second annual Cancer Survivorship Symposium in the USA. Significant opportunity exists to include assessment of iron overload using FerriScan into the American Society of Clinical Oncology (ASCO) guidelines for survivorship care. In addition, discussions were held with several key patient advocacy groups to leverage the Company's patient advocacy engagement plan to raise awareness of iron toxicity and FerriScan. Key contact with clinicians was also made with the intention of furthering relationships to set up FerriScan at new sites.

**Collaboration**

Researchers at Masonic Cancer Center, University of Minnesota, published a study in the peer-reviewed Journal of Pediatric Hematology/Oncology looking at rates of iron overload in young cancer survivors. The results are based on monitoring data gathered using FerriScan. To read the latest publication abstract please click the *“Iron Overload in Survivors of Childhood Cancer”* link at [www.resonancehealth.com/publications-info](http://www.resonancehealth.com/publications-info).

In 2016 Resonance Health commenced a collaboration with the University of Minnesota and the University of Western Australia to gain a better understanding of the characteristics of iron overload in paediatric cancer survivors. Results from this collaboration are anticipated to be presented at a premiere haematology conference and published later this year. This increased publicity of the concerns of iron toxicity in cancer survivors will help to spread awareness and drive the uptake of optimal monitoring of iron overload using the FerriScan technology.

Resonance Health is pleased with progress to date on the strategically targeted cancer campaign and will continue to monitor the results of its efforts. Key collaborations have been initiated and are being progressed. The positive survey response supports the strategy to further roll out of the campaign to promote the monitoring of cancer survivors for transfusional iron overload using FerriScan and for fatty liver using HepaFat-Scan.

**For further information please contact:**

Sander Bangma

General Manager, Resonance Health

E: [SanderB@resonancehealth.com](mailto:SanderB@resonancehealth.com) P: +61 (0)8 9286 5300